KRAS and cancer: Variants such as mutant KRAS that re‐activate downstream signalling pathways can rescue the erlotinib‐induced lethality in this cell type.34 In addition, previous study also used the method which lnRNAs were mutually exclusive with well‐known cancer driver genes to distinguish driver lncRNA from passengers.35 In the present study, the co‐occurrence of mutations was used to explore the cooperative mechanism of genes and lncRNAs in OSCC.